Humacyte begins phase 2 Humacyl vascular trauma trial
Humacyl vascular trauma trial : Humacyte, a regenerative medical technology company, has started a phase 2 clinical trial of its investigational human acellular vessel (HAV) – Humacyl for vascular replacement or reconstruction in patients suffering from life- or limb-threatening vascular trauma. Humacyl is a bioengineered human acellular vessel which has been designed to significantly improve […]